Palkion Inc.

CrystalGenomics Inc. and ProQuest Investments formed Palkion Inc. to identify and develop orally available anemia drugs that modulate the HIF prolyl hydroxylase enzyme system. Palkion is finishing up preclinical toxicology on its lead candidate for anemia associated with chronic kidney disease.